Welcome to our dedicated page for Sage Therapeutic SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings for Sage Therapeutics, Inc. (former Nasdaq: SAGE), a biopharmaceutical company focused on brain health and postpartum depression. These documents include current reports on Form 8-K, delisting notices, and deregistration filings that together describe key corporate, regulatory, and capital markets events in the company’s history.
For Sage, recent Form 8-K filings detail the Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc., the tender offer process, and the subsequent merger in which Saphire, Inc., a wholly owned subsidiary of Supernus, merged with and into Sage Therapeutics. The 8-K filed on July 31, 2025, explains that, as a result of this transaction, Sage became a wholly owned subsidiary of Supernus and that a change in control occurred. It also describes the treatment of equity awards, changes in directors and officers, and amendments to the company’s certificate of incorporation.
Filings related to Sage’s trading status are particularly important for investors researching the SAGE symbol. A Form 25 filed by The Nasdaq Stock Market LLC on July 31, 2025, covers the removal of Sage’s common stock from listing and registration on The Nasdaq Global Market under Section 12(b) of the Exchange Act. Subsequently, Sage filed a Form 15 on August 11, 2025, certifying the termination of registration of its common stock under Section 12(g) and the suspension of its reporting obligations under Sections 13 and 15(d). Together, these filings document Sage’s transition from a publicly traded company to a wholly owned subsidiary with suspended Exchange Act reporting.
Earlier and related filings, including 8-Ks furnishing quarterly financial results, provide additional context on Sage’s collaboration revenue from ZURZUVAE, research and development expenses, restructuring activities, and strategic alternatives review. On Stock Titan, AI-powered tools can help users quickly interpret these complex filings by highlighting key sections, summarizing major events such as acquisitions and delistings, and pointing to items that may be relevant for understanding Sage’s historical financial condition, changes in control, and the regulatory record associated with the SAGE ticker.
Sage Therapeutics (SAGE) reported insider trading activity through a Form 4 filing for Chief Scientific Officer and Interim Head of R&D Michael C. Quirk. On June 24, 2025, Quirk disposed of 113 shares at a price of $9.22 per share through a tax withholding transaction (Code F).
The transaction was related to the vesting of 338 time-based restricted stock units (RSUs) that were originally granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan. The RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments.
Following the reported transaction, Quirk directly owns 30,461 shares of Sage Therapeutics common stock. The Form 4 was filed on behalf of Quirk by attorney-in-fact Brandon Marsh on June 26, 2025.
Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics (SAGE), reported a Form 4 filing on June 28, 2025, detailing changes in beneficial ownership.
Key transaction details:
- On June 24, 2025, Shiferman had 79 shares withheld for tax purposes at a price of $9.22 per share
- The withholding was related to the vesting of 234 time-based restricted stock units (RSUs) granted on October 28, 2021
- These RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments
- Following the transaction, Shiferman directly owns 30,950 shares of common stock
The transaction was executed under the company's 2014 Stock Option and Incentive Plan, with Brandon Marsh signing as attorney-in-fact for Shiferman on June 26, 2025.